On May 26, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that six clinical abstracts demonstrating the broad use of its NeXT Personal test will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 to June 2 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal’s single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC). By detecting circulating tumor DNA (ctDNA) at these ultra-low thresholds, NeXT Personal continues to set new benchmarks for MRD test performance.

"At ASCO (Free ASCO Whitepaper), our collaborators will present data that underscores the critical importance of ultrasensitive MRD testing across six distinct solid tumor types, including exceptional new data in colorectal and lung cancer," said Richard Chen, MD, President and Chief Medical Officer of Personalis. "This data builds upon foundational evidence from our landmark publications in breast cancer, lung cancer, and immunotherapy monitoring, confirming that the ultrasensitive detection provided by NeXT Personal enables early identification of recurrence and precise assessments of therapy response."

Key clinical highlights at ASCO (Free ASCO Whitepaper) include:

Ultrasensitive Colorectal Cancer Data (VICTORI Study): Updated results from the prospective VICTORI surveillance cohort, led by the University of British Columbia, highlight NeXT Personal’s strong performance in detecting ctDNA among Stage I-III colorectal cancer patients. The test achieved 100% longitudinal sensitivity for recurrence—including difficult-to-detect metastatic sites—and >80% landmark sensitivity as early as four weeks post-surgery.
Clinical Importance of Ultrasensitive ctDNA Detection at Single-Digit Levels (TRACERx Podium Presentation): Utilizing samples from the TRACERx lung cancer cohort, investigators demonstrate that NeXT Personal ctDNA detections at the very lowest levels <10ppm identify patients at high risk for relapse.
Expanded Clinical Evidence for NeXT Personal Across Solid Tumor Types: New clinical data will be presented across six cancer types, including colorectal, lung, melanoma, ovarian, endometrial, and renal cell cancers.
Presentation Schedule

Oral Podium Presentation

Title: Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer (TRACERx)
Presenter: Jonathan Wan, MD, PhD, University College London
Abstract: #8017 | Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Time: May 31, 2026, 4:30 PM–6:00 PM CDT
Poster Presentations

Colorectal Cancer (VICTORI Study): Minimal residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: Updates from the VICTORI study. (University of British Columbia). Abstract #396 | Session: Gastrointestinal Cancer | Time: May 30, 2026, 9:00 AM–12:00 PM CDT
Renal Cell Carcinoma: Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma. (Instituto de Investigación Sanitaria – IDIS). Abstract #30 | Session: Genitourinary Cancer | Time: May 31, 2026, 9:00 AM–12:00 PM CDT
Melanoma: Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy. (University Medical Center Hamburg-Eppendorf – UKE). Abstract #288 | Session: Melanoma/Skin Cancers | Time: May 31, 2026, 9:00 AM–12:00 PM CDT
Endometrial Cancer: Ultra-sensitive circulating tumor DNA (ctDNA) detection as a predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment. (MD Anderson Cancer Center). Abstract #277 | Session: Gynecologic Cancer | Time: June 1, 2026, 9:00 AM–12:00 PM CDT
Ovarian Cancer: Circulating tumor DNA enhances detection of high-risk minimal residual disease in ovarian cancer relative to second-look laparoscopy. (MD Anderson Cancer Center). Abstract #233 | Session: Gynecologic Cancer | Time: June 1, 2026, 9:00 AM–12:00 PM CDT

(Press release, Personalis, MAY 26, 2026, View Source [SID1234666077])